

BeOne Medicines (ONC US)

Hematology dominance meets solid tumor inflection

BeOne reported robust 2Q26 results and improving profitability, prompting management to raise FY26 guidance. We see significant upside for Brukinsa's global BTK market share expansion. Furthermore, BeOne's solid tumor pipeline is at an inflection point. Upcoming data readouts at ESMO present compelling catalysts for valuation upside. We maintain BUY rating with TP of US\$442.31.

■ **Strong 2Q26 results and raised FY26 guidance.** BeOne delivered robust 2Q26 results, prompting an upward revision of its FY26 guidance. Total 2Q26 revenue reached US\$1.71bn (+30% YoY, +13% QoQ), fueled by Brukinsa generating US\$1.25bn globally (+31% YoY, +14% QoQ), maintaining its leadership as the top-selling global BTK inhibitor. Adjusted non-GAAP operating profit surged to US\$503mn in 2Q26 (vs. US\$275mn in 2Q25). This bottom-line expansion was driven by robust sales, an improved 90% product gross margin, and a reduced 35% SG&A ratio. For 1H26, revenue of US\$3.22bn and adjusted operating profit of US\$917mn accounted for 50% and 63% of our previous full-year forecasts, beating our expectations. Consequently, management raised FY26 guidance for revenue to US\$6.6–6.8bn and adjusted operating profit to US\$1.7–1.8bn.

■ **Brukinsa 1L MCL success and Beqalzi approval expand hematology franchise.** Brukinsa's Ph3 MANGROVE trial met its primary endpoint; the chemo-free Brukinsa plus rituximab regimen reduced progression/death risk by 43% versus bendamustine plus rituximab (BR). This establishes a new standard in a >21,000 patients/year market, outperforming the 27% risk reduction from the acalabrutinib plus BR chemo-regimen. Beqalzi (BCL2i) secured FDA approval for BTKi-treated MCL. Although the uMRD analysis of Beqalzi plus Brukinsa versus V+O in 1L CLL missed statistical superiority, we eagerly await the PFS data, noting that lower uMRD rates in the V+I versus V+O comparison still yielded similar PFS. In addition, we also anticipate a US NDA submission for the BTK CDAC in R/R CLL in 2H26.

■ **Multiple near-term solid tumor catalysts.** Solid tumor development has reached an inflection point. At ASCO, promising PoC data were released for CDK4i, GPC3x4-1BB bsAb and B7-H4 ADC (CMBI report [link](#)). The CDK4i showed a differentiated hematological safety profile, with a global Ph3 in 1L HR+/HER2- breast cancer already enrolling. The GPC3x4-1BB bsAb demonstrated strong efficacy in 2L+ HCC and is being studied in combo with tislelizumab plus bevacizumab for 1L HCC; its China registration-enabling cohort in 3L+ HCC is fully enrolled, with a global Ph3 in 2L HCC slated by YE26. Updates on the bsAb, plus PoC data for PRMT5i and CEA ADC, will be presented at ESMO in October. Initiations of Ph3 trials for PRMT5i and CEA ADC in NSCLC are expected in 2027. We also see combo potential for PRMT5i with Pan-RAS in PDAC and potentially NSCLC, while CEA ADC could combine with PD-1 in 1L NSCLC. In addition, B7-H4 ADC is positioned for Ph3 initiation in 1L ovarian cancer by YE26.

■ **Maintain BUY.** We expect BeOne to deliver robust FY26 earnings, further supporting rapid progress in its R&D pipeline. Factoring in the strong 1H26 sales growth and improving profitability, we revise our TP from US\$392.43 to US\$442.31 (WACC 9.64%, terminal growth rate 3.5%, both unchanged).

Earnings Summary

(YE 31 Dec)	FY24A	FY25A	FY26E	FY27E	FY28E
Revenue (US\$ mn)	3,810	5,343	6,721	7,798	8,760
Net profit (US\$ mn)	(644.8)	286.9	915.8	1,286.3	1,846.2
EPS (Reported) (US\$)	(6.12)	2.63	7.72	10.85	15.57
P/S (x)	10.3	7.3	5.8	5.0	4.5
P/E (x)	ns	125.4	42.7	30.4	21.2

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price	US\$442.31
(Previous TP)	US\$392.43)
Up/Downside	34.1%
Current Price	US\$329.80

China Healthcare

Jill WU, CFA
(852) 3900 0842
jillwu@cmbi.com.hk

Andy WANG
(852) 3657 6288
andywang@cmbi.com.hk

Stock Data

Mkt Cap (US\$ mn)	39,104.6
Avg 3 mths t/o (US\$ mn)	31.5
52w High/Low (US\$)	377.47/260.27
Total Issued Shares (mn)	118.6
Source: FactSet	

Shareholding Structure


Amgen	17.1%
Baker Bros	8.0%
Source: Bloomberg	

Share Performance

	Absolute	Relative
1-mth	6.7%	4.6%
3-mth	4.0%	1.9%
6-mth	-6.8%	-18.5%

Source: FactSet

12-mth Price Performance



Source: FactSet

Figure 1: Risk-adjusted DCF valuation

DCF valuation (US\$ mn)	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E
EBIT	1,030	1,479	2,112	2,571	3,408	4,310	5,127	5,415	5,464	5,436
Tax rate	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%
EBIT*(1-tax rate)	875	1,257	1,796	2,186	2,897	3,664	4,358	4,603	4,645	4,621
+ D&A	146	151	151	150	146	143	139	136	133	131
- Change in working capital	-81	-169	-151	-105	-219	-194	-171	-66	-21	17
- Capex	-200	-200	-150	-150	-100	-100	-100	-100	-100	-100
FCFF	741	1,039	1,645	2,081	2,724	3,512	4,226	4,573	4,657	4,669
Terminal value										78,695
PV of enterprise (US\$ mn)	47,624									
Net debt (US\$ mn)	-4,821									
Equity value (US\$ mn)	52,444									
No. of ADS (mn)	119									
DCF per ADS (US\$)	442.31									
Terminal growth rate	3.5%									
WACC	9.64%									
Cost of equity	13.0%									
Cost of debt	4.0%									
Equity beta	1.00									
Risk-free rate	3.0%									
Market risk premium	10.0%									
Target debt to asset ratio	35.0%									
Effective corporate tax rate	15.0%									

Source: CMBIGM estimates

Figure 2: Sensitivity analysis (US\$)

Terminal growth rate	WACC				
	8.64%	9.14%	9.64%	10.14%	10.64%
4.5%	620.02	551.71	496.80	451.73	414.09
4.0%	571.41	514.14	467.14	427.89	394.65
3.5%	532.26	483.23	442.31	407.65	377.94
3.0%	500.04	457.36	421.21	390.24	363.41
2.5%	473.08	435.38	403.08	375.11	350.67

Source: CMBIGM estimates

Figure 3: CMBIGM forecast revision

US\$ mn	NEW			OLD			Diff (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	6,721	7,798	8,760	6,421	7,378	8,233	5%	6%	6%
Gross profit	5,992	6,962	7,829	5,617	6,477	7,251	7%	7%	8%
Operating profit	1,070	1,514	2,142	805	1,516	2,205	33%	0%	-3%
Net profit	916	1,286	1,846	752	1,329	1,933	22%	-3%	-4%
EPS (US\$)	7.72	10.85	15.57	6.35	11.22	16.31	22%	-3%	-5%
Gross margin	89.16%	89.27%	89.38%	87.49%	87.78%	88.08%	+1.67 ppt	+1.49 ppt	+1.30 ppt
Operating margin	15.92%	19.41%	24.46%	12.54%	20.54%	26.78%	+3.38 ppt	-1.13 ppt	-2.33 ppt
Net margin	13.63%	16.49%	21.08%	11.72%	18.01%	23.48%	+1.91 ppt	-1.52 ppt	-2.40 ppt

Source: Bloomberg, CMBIGM estimates

Figure 4: CMBIGM estimates vs consensus

US\$ mn	CMBIGM			Consensus			Diff (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	6,721	7,798	8,760	6,594	7,633	8,644	2%	2%	1%
Gross profit	5,992	6,962	7,829	5,797	6,748	7,637	3%	3%	3%
Operating profit	1,070	1,514	2,142	973	1,505	2,035	10%	1%	5%
Net profit	916	1,286	1,846	895	1,306	1,720	2%	-2%	7%
EPS (US\$)	7.72	10.85	15.57	7.10	10.57	12.96	9%	3%	20%
Gross margin	89.16%	89.27%	89.38%	87.91%	88.40%	88.35%	+1.24 ppt	+0.87 ppt	+1.03 ppt
Operating margin	15.92%	19.41%	24.46%	14.75%	19.72%	23.54%	+1.17 ppt	-0.31 ppt	+0.92 ppt
Net margin	13.63%	16.49%	21.08%	13.57%	17.11%	19.90%	+0.05 ppt	-0.62 ppt	+1.18 ppt

Source: Bloomberg, CMBIGM estimates

Financial Summary

INCOME STATEMENT	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (US\$ mn)						
Revenue	2,459	3,810	5,343	6,721	7,798	8,760
Cost of goods sold	(380)	(594)	(669)	(729)	(836)	(931)
Gross profit	2,079	3,216	4,674	5,992	6,962	7,829
Operating expenses	(3,287)	(3,784)	(4,227)	(4,922)	(5,448)	(5,687)
SG&A expense	(1,505)	(1,831)	(2,081)	(2,438)	(2,686)	(2,843)
R&D expense	(1,779)	(1,953)	(2,146)	(2,484)	(2,762)	(2,843)
Others	(4)	0	0	0	0	0
Other income	382	35	(30)	8	(0)	30
Pre-tax profit	(826)	(533)	417	1,077	1,513	2,172
Income tax	(56)	(112)	(130)	(162)	(227)	(326)
Minority interest	0	0	0	0	0	0
Net profit	(882)	(645)	287	916	1,286	1,846
Adjusted net profit	(882)	(645)	287	916	1,286	1,846

BALANCE SHEET	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (US\$ mn)						
Current assets	4,203	3,992	6,234	7,399	9,005	11,410
Cash & equivalents	3,172	2,627	4,548	5,640	7,019	9,225
Account receivables	358	676	865	956	1,107	1,243
Inventories	416	495	608	591	667	730
Financial assets at FVTPL	3	0	0	0	0	0
Other current assets	255	193	213	213	213	213
Non-current assets	1,602	1,929	1,955	2,009	2,058	2,058
PP&E	1,324	1,578	1,642	1,695	1,745	1,744
Deferred income tax	0	0	0	0	0	0
Intangibles	57	51	63	63	63	63
Other non-current assets	221	300	251	251	251	251
Total assets	5,805	5,921	8,189	9,408	11,063	13,467
Current liabilities	1,810	2,215	1,829	1,822	1,880	1,927
Short-term borrowings	688	852	57	57	57	57
Account payables	315	405	479	472	530	577
Tax payable	23	26	42	42	42	42
Other current liabilities	784	932	1,251	1,251	1,251	1,251
Non-current liabilities	458	374	1,148	948	748	748
Long-term borrowings	198	166	962	762	562	562
Deferred income	0	0	0	0	0	0
Other non-current liabilities	260	207	186	186	186	186
Total liabilities	2,268	2,589	2,977	2,770	2,628	2,675
Share capital	11,599	12,088	12,759	13,270	13,781	14,292
Retained earnings	(7,962)	(8,607)	(8,320)	(7,404)	(6,118)	(4,272)
Other reserves	(99)	(149)	(78)	(78)	(78)	(78)
Total shareholders equity	3,537	3,332	4,361	5,788	7,585	9,942
Minority interest	0	0	0	0	0	0
Total equity and liabilities	5,805	5,921	8,189	9,408	11,063	13,467

CASH FLOW	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (US\$ mn)						
Operating						
Profit before taxation	(826)	(533)	417	1,077	1,513	2,172
Depreciation & amortization	88	172	142	146	151	151
Tax paid	(56)	(112)	(130)	(162)	(227)	(326)
Others	(363)	332	699	430	342	359
Net cash from operations	(1,157)	(141)	1,128	1,492	1,779	2,356
Investing						
Capital expenditure	(562)	(493)	(186)	(200)	(200)	(150)
Acquisition of subsidiaries/ investments	(17)	(22)	(12)	0	0	0
Net proceeds from disposal of short-term investments	673	3	3	0	0	0
Others	(34)	(36)	(82)	0	0	0
Net cash from investing	60	(548)	(276)	(200)	(200)	(150)
Financing						
Net borrowings	684	877	1,084	0	0	0
Proceeds from share issues	0	0	907	0	0	0
Others	(268)	(684)	(932)	(200)	(200)	0
Net cash from financing	416	193	1,059	(200)	(200)	0
Net change in cash						
Cash at the beginning of the year	3,875	3,186	2,639	4,548	5,640	7,019
Exchange difference	(8)	(52)	60	0	0	0
Cash at the end of the year	3,186	2,639	4,610	5,640	7,019	9,225
GROWTH	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Revenue	73.7%	55.0%	40.2%	25.8%	16.0%	12.3%
Gross profit	84.1%	54.7%	45.3%	28.2%	16.2%	12.5%
Net profit	na	na	na	219.2%	40.4%	43.5%
Adj. net profit	na	na	na	219.2%	40.4%	43.5%
PROFITABILITY	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Gross profit margin	84.5%	84.4%	87.5%	89.2%	89.3%	89.4%
Adj. net profit margin	(35.9%)	(16.9%)	5.4%	13.6%	16.5%	21.1%
Return on equity (ROE)	(22.3%)	(18.8%)	7.5%	18.0%	19.2%	21.1%
GEARING/LIQUIDITY/ACTIVITIES	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Net debt to equity (x)	(0.7)	(0.5)	(0.8)	(0.8)	(0.8)	(0.9)
Current ratio (x)	2.3	1.8	3.4	4.1	4.8	5.9
Receivable turnover days	39.4	49.5	52.6	52.6	52.6	52.6
Inventory turnover days	335.5	279.9	301.2	296.2	291.2	286.2
Payable turnover days	293.0	221.2	241.3	236.3	231.3	226.3
VALUATION	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
P/E	ns	ns	125.4	42.7	30.4	21.2
P/E (diluted)	ns	ns	130.4	42.7	30.4	21.2
P/B	126.5	135.5	107.2	87.8	67.0	51.1

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report. Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.